Y Intercept Hong Kong Ltd Sells 8,308 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Y Intercept Hong Kong Ltd decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 55.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,642 shares of the medical research company’s stock after selling 8,308 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in IQVIA were worth $1,305,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of IQV. Capital Performance Advisors LLP purchased a new position in IQVIA during the third quarter worth $27,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter worth about $33,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. raised its position in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in IQVIA in the third quarter worth about $57,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IQV. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. UBS Group cut their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Trading Down 0.1 %

Shares of NYSE IQV opened at $190.77 on Thursday. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The business has a fifty day moving average price of $199.40 and a 200 day moving average price of $215.46. The stock has a market capitalization of $33.59 billion, a P/E ratio of 25.44, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.